NGeneBio drastically lowers rights offering estimated price to 1,074 KRW, reducing proceeds to 7.68B KRW - deepening existing shareholder dilution
NGeneBio amended its rights offering disclosure on July 20, 2026, drastically lowering the estimated issue price from 3,135 KRW to 1,074 KRW, a 66% reduction.
While the total number of new shares remains at 7.15 million, the expected proceeds shrink from approximately 22.4 billion KRW to 7.68 billion KRW, forcing adjustments in the stated use of funds: operating funds reduced from 17.3 billion to 3.68 billion KRW and debt repayment from 5.1 billion to 4.0 billion KRW.
The offering still represents a massive 80% dilution of existing shares, and the lower issue price exacerbates the value transfer from current shareholders.
The subscription schedule remains unchanged: rights offering for existing shareholders on September 9-10, payment on September 17, and listing of new shares on October 2.
[AI Summary]This amendment signals a significant downward revision in the offering price, implying weaker market conditions and reduced capital inflow. The severe dilution and lowered proceeds increase downside risk for shareholders, who must actively participate in the rights offering or sell rights to mitigate losses. The repeated amendments also raise governance concerns.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)